LA JOLLA, Calif.
April 7, 2014
/PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that three abstracts will be presented in poster presentation sessions during the American Association for Cancer Research (AACR) Annual Meeting, which will be held
April 5-9, 2014
San Diego, CA.
An oral presentation will also be presented by Regulus' strategic alliance partner, Sanofi. Data to be presented include preclinical studies investigating the therapeutic potential of targeting microRNA-21 ("miR-21") and microRNA-221 ("miR-221") for the treatment of hepatocellular carcinoma ("HCC"), the most common form of liver cancer, and biomarker discovery studies evaluating the pharmacodynamics signature for assessing miR-221 inhibition and microRNA expression in tumor tissues in mouse models of HCC. Each poster, after the time of its presentation, can be accessed on the investor relations page of Regulus' website,
- Poster Session on miR-221 - April 7, 2014 8:00 a.m. - 12:00 p.m. PDT
- miR-221: a Potential Therapeutic Target for Hepatocellular Carcinoma
- A miR-221 Multigene Pharmacodynamics Signature for Assessing miR-221 Inhibition
- Oral Presentation by Sanofi on miR-21 – April 8, 2014 3:35 p.m. PDT
- Targeting microRNA-21 in Hepatocellular Carcinoma
- Poster Session on microRNA Expression - April 9, 2014 8:00 a.m. - 12:00 p.m. PDT
- Serum microRNAs Reflect microRNA Expression in Tumor Tissues as Well as Systemic Response to Disease in HRAS-driven Mouse Models of HCC
"Utilizing both genetic and pharmacological approaches, the data to be presented at AACR provide further evidence that miR-21 and miR-221 are validated preclinical targets for the treatment of hepatocellular carcinoma," said
Neil W. Gibson
, Ph.D., Chief Scientific Officer of Regulus. "In addition, we've made progress to develop gene signatures that enable demonstration of target inhibition in tumor tissues. We believe these gene signatures and the overall approach enable Regulus to demonstrate proof of mechanism in preclinical studies which may be translated into useful biomarker signatures in potential future clinical trials."
Update on Regulus' Liver Cancer Intellectual Property Estate
As part of Regulus' rich intellectual property estate, Regulus controls patent rights related to the modulation of multiple different microRNAs for the treatment of liver cancer. Regulus has already received patents in
the United States
for targeting multiple different microRNAs, including miR-21 and miR-221/222, for the treatment of liver cancer. Also included in the Regulus portfolio are fundamental patent rights claiming methods of treating liver cancer with mimics of microRNA-34a, one of the most well-validated tumor suppressor microRNAs.
Today, Regulus is pleased to announce receipt of a Decision to Grant a Patent from the Japan Patent Office for the use of anti-miRs targeting multiple different microRNAs, including miR-21 and miR-222, for the treatment of liver cancer.